Drugs for Protoporphyria, Erythropoietic, 1 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):
(show all 25)
# |
|
Name |
Status |
Phase |
Clinical Trials |
Cas Number |
PubChem Id |
1 |
|
Afamelanotide |
Approved, Investigational |
Phase 3 |
|
75921-69-6 |
16132954 16197727 |
Synonyms:
α-NDP-MSH|[Nle4,dPhe7]α-MSH|CUV-1647|CUV1647|NDP-MSH|Scenesse®
4-({1-[(1-{[1-({1-[({[6-amino-1-(2-{[1-(C-hydroxycarbonimidoyl)-2-methylpropyl]-C-hydroxycarbonimidoyl}pyrrolidin-1-yl)-1-oxohexan-2-yl]-C-hydroxycarbonimidoyl}methyl)-C-hydroxycarbonimidoyl]-2-(1H-indol-3-yl)ethyl}-C-hydroxycarbonimidoyl)-4-carbamimidamidobutyl]-C-hydroxycarbonimidoyl}-2-phenylethyl)-C-hydroxycarbonimidoyl]-2-(1H-imidazol-5-yl)ethyl}-C-hydroxycarbonimidoyl)-4-({2-[(2-{[2-({1,3-dihydroxy-2-[(1-hydroxyethylidene)amino]propylidene}amino)-1-hydroxy-3-(4-hydroxyphenyl)propylidene]amino}-1,3-dihydroxypropylidene)amino]-1-hydroxyhexylidene}amino)butanoate
AFAMELANOTIDE
CUV1647
CUV-1647
|
Melanotan 1
Melanotan I
Melanotan-1
MT-I
SCENESSE
|
|
2 |
|
Colestipol |
Approved |
Phase 2, Phase 3 |
|
26658-42-4 |
62816 |
Synonyms:
|
COPOLYMER OF BIS(2-AMINOETHYL)AMINE AND 2-(CHLOROMETHYL)OXIRANE
EPICHLOROHYDRIN-TETRAETHYLENEPENTAMINE POLYMER
|
|
3 |
|
Cysteine |
Approved, Nutraceutical |
Phase 3 |
|
52-90-4 |
594 5862 |
Synonyms:
(+)-2-AMINO-3-MERCAPTOPROPIONIC ACID
(2R)-2-AMINO-3-MERCAPTOPROPANOATE
(2R)-2-AMINO-3-MERCAPTOPROPANOIC ACID
(2R)-2-AMINO-3-MERCAPTO-PROPANOIC ACID
(2R)-2-AMINO-3-SULFANYLPROPANOATE
(2R)-2-AMINO-3-SULFANYLPROPANOIC ACID
(2R)-2-AMINO-3-SULFANYL-PROPANOIC ACID
(2R)-2-Amino-3-sulphanylpropanoate
(2R)-2-Amino-3-sulphanylpropanoic acid
(R)-(+)-CYSTEINE
(R)-2-AMINO-3-MERCAPTOPROPANOATE
(R)-2-AMINO-3-MERCAPTO-PROPANOATE
(R)-2-AMINO-3-MERCAPTOPROPANOIC ACID
(R)-2-AMINO-3-MERCAPTO-PROPANOIC ACID
(R)-CYSTEINE
2-Amino-3-mercaptopropanoate
2-Amino-3-mercaptopropanoic acid
2-Amino-3-mercaptopropionate
2-Amino-3-mercaptopropionic acid
2-Amino-3-sulfanylpropanoate
2-Amino-3-sulfanylpropanoic acid
2-Amino-3-sulphanylpropanoate
2-Amino-3-sulphanylpropanoic acid
3-MERCAPTO-L-ALANINE
ACETYLCYSTEINE
ALPHA-AMINO-BETA-THIOLPROPIONIC ACID
BETA-MERCAPTOALANINE
B-MERCAPTOALANINE
C
CARBOCYSTEINE
Cisteina
|
CISTEINUM
Cys
Cystein
Cysteine
CYSTEINE HCL
Cysteine hydrochloride
CYSTEINUM
E 920
E920
E-920
E921
Ecolan
FREE CYSTEINE
Half cystine
Half-cystine
Hcys
L Cysteine
L-(+)-CYSTEINE
L-2-AMINO-3-MERCAPTOPROPANOATE
L-2-AMINO-3-MERCAPTOPROPANOIC ACID
L-2-Amino-3-mercaptopropionate
L-2-AMINO-3-MERCAPTOPROPIONIC ACID
L-CYS
L-CYSTEIN
L-Cysteine
L-ZYSTEIN
POLYCYSTEINE
THIOSERINE
Zinc cysteinate
Zystein
|
|
4 |
|
Antimetabolites |
|
Phase 2, Phase 3 |
|
|
|
5 |
|
Hypolipidemic Agents |
|
Phase 2, Phase 3 |
|
|
|
6 |
|
Lipid Regulating Agents |
|
Phase 2, Phase 3 |
|
|
|
7 |
|
Dermatologic Agents |
|
Phase 3 |
|
|
|
8 |
|
Histamine |
Approved, Investigational |
Phase 2 |
|
51-45-6 |
774 |
Synonyms:
1H-Imidazole-4-ethanamine
2-(1H-Imidazol-4-yl)ethanamine
2-(1H-Imidazol-4-yl)ethylamine
2-(1H-Imidazol-5-yl)ethanamine
2-(1H-Imidazol-5-yl)ethylamine
2-(3H-Imidazol-4-yl)ethylamine
2-(4-Imidazolyl)ethanamine
2-(4-Imidazolyl)ethylamine
2-Imidazol-4-ylethylamine
2-Imidazol-4-yl-ethylamine
4-(2-Aminoethyl)-1H-imidazole
4-(2-Aminoethyl)imidazole
4-Imidazoleethylamine
5-Imidazoleethylamine
|
beta-Aminoethylglyoxaline
beta-Aminoethylimidazole
beta-Aminothethylglyoxaline
beta-Imidazolyl-4-ethylamine
b-Imidazolyl-4-ethylamine
Eramin
Ergamine
Ergotidine
Histamine
HSM
Imidazole-4-ethylamine
NSC-33792
Î’-imidazolyl-4-ethylamine
|
|
9 |
|
Cimetidine |
Approved, Investigational |
Phase 2 |
|
51481-61-9 |
2756 |
Synonyms:
1-Cyano-2-methyl-3-(2-(((5-methyl-4-imidazolyl)methyl)thio)ethyl)guanidine
2-Cyano-1-methyl-3-(2-(((5-methylimidazol-4-yl)methyl)thio)ethyl)guanidine
ACID-EZE
ACITAK 200
ACITAK 400
ACITAK 800
Altramet
Biomet
Biomet400
BRUMETADINA
Cimetag
CIMETIDIN
Cimetidina
CIMETIDINE
CIMÉTIDINE
Cimetidine HCL
cimetidine HCl|Tagamet®
Cimetidine hydrochloride
Cimetidinum
DYSPAMET
Eureceptor
GALENAMET
HCL, Cimetidine
Histodil
|
Hydrochloride, cimetidine
KENTAMET
N-Cyano-n'-methyl-n''-(2-(((5-methyl-1H-imidazol-4-yl)methyl)thio)ethyl)guanidine
N-Cyano-n'-methyl-n''-(2-([(5-methyl-1H-imidazol-4-yl)methyl]sulfanyl)ethyl)guanidine
N-Cyano-n'-methyl-n''-(2-([(5-methyl-1H-imidazol-4-yl)methyl]sulphanyl)ethyl)guanidine
N''-cyano-N-methyl-n'-(2-{[(5-methyl-1H-imidazol-4-yl)methyl]thio}ethyl)guanidine
NSC-335308
PEPTIMAX 200
PEPTIMAX 400
PEPTIMAX 800
SK And F 92334
SK And F92334
SK And F-92334
SKF-92334
TAGADINE
Tagamet
TAGAMET 100
TAGAMET HB
Tagamet HB 200
Ulcerfen
ULTEC
VALMAGEN
ZITA
|
|
10 |
|
Protoporphyrin |
Experimental |
Phase 2 |
|
553-12-8 |
|
Synonyms:
3,3'-(3,7,12,17-Tetramethyl-8,13-divinyl-21H,23H-porphine-2,18-diyl)-bis-propionate
3,3'-(3,7,12,17-Tetramethyl-8,13-divinyl-21H,23H-porphine-2,18-diyl)-bis-propionic acid
3,3'-(3,7,12,17-Tetramethyl-8,13-divinylporphine-2,18-diyl)di
3,7,12,17-Tetramethyl-8,13-divinylporphyrin-2,18-dipropanoate
3,7,12,17-Tetramethyl-8,13-divinylporphyrin-2,18-dipropanoic acid
H2PpIX
Kammerer's prophyrin
|
Ooporphyrin
Porphyrinogen IX
PpIX
Protoporphyrin
Protoporphyrin IX
Protoporphyrin-"ix"
Protoporphyrin-IX
|
|
11 |
|
Anti-Ulcer Agents |
|
Phase 2 |
|
|
|
12 |
|
Neurotransmitter Agents |
|
Phase 2 |
|
|
|
13 |
|
Antacids |
|
Phase 2 |
|
|
|
14 |
|
Histamine phosphate |
|
Phase 2 |
|
51-74-1 |
134614 |
Synonyms:
2)
4-(2-AMINOETHYL)IMIDAZOLE BIS(DIHYDROGEN PHOSPHATE)
4-(2-AMINOETHYL)IMIDAZOLE DI-ACID PHOSPHATE
HISTAMINE ACID PHOSPHATE
|
HISTAMINE BIPHOSPHATE
HISTAMINE DIHYDROGEN PHOSPHATE
HISTAMINE DIPHOSPHATE
HISTAMINE PHOSPHATE (1
|
|
15 |
|
Histamine H2 Antagonists |
|
Phase 2 |
|
|
|
16 |
|
Histamine Antagonists |
|
Phase 2 |
|
|
|
17 |
|
Cytochrome P-450 Enzyme Inhibitors |
|
Phase 2 |
|
|
|
18 |
|
Gastrointestinal Agents |
|
Phase 2 |
|
|
|
19 |
|
Iron |
Approved |
|
|
7439-89-6 |
29936 |
Synonyms:
Carbonyl iron
Eisen
Electrolytic iron
Fe
FE (III) ion
Fe(3+)
Fe(III)
fer
Ferric ion
Ferric iron
Ferrum
|
Ferrum metallicum
Hierro
Iron powder
Iron(3+)
Iron, carbonyl
Iron, electrolytic
Iron, elemental
Iron, ion (fe(3+))
Iron, reduced
Reduced iron
|
|
20 |
|
Aminolevulinic acid |
Approved |
|
|
106-60-5 |
137 |
Synonyms:
5 Aminolaevulinate
5 Aminolevulinate
5-ALA
5-Amino-4-oxopentanoate
5-Amino-4-oxo-pentanoate
5-Amino-4-oxopentanoic acid
5-Amino-4-oxo-pentanoic acid
5-Amino-4-oxovalerate
5-Amino-4-oxovaleric acid
5-Aminolaevulinate
5-Aminolaevulinic acid
5-Aminolevulinate
5-Amino-levulinate
5-Aminolevulinic acid
5-Amino-levulinic acid
Acid hydrochloride, aminolevulinic
Acid, aminolevulinic
Acid, Delta-aminolevulinic
|
ácido 5-aminolevulínico
Aladerm
Aminolevulinate
Aminolevulinic acid
Amino-levulinic acid
Aminolevulinic acid hydrochloride
Bertek brand OF aminolevulinic acid hydrochloride
dALA
Delta Aminolevulinic acid
delta-ALA
delta-Aminolevulinate
delta-Aminolevulinic acid
Hydrochloride, aminolevulinic acid
Kerastick
Levulan
δ-ALA
Δ-aminolevulinate
δ-aminolevulinic acid
|
|
21 |
|
Isoniazid |
Approved, Investigational |
|
|
54-85-3 |
3767 |
Synonyms:
4-Pyridinecarbohydrazide
Acid vanillylidenehydrazide, isonicotinic
Andrazide
Antimicina
Antituberkulosum
Armacide
Armazid
Armazide
Atcotibine
Azuren
Bacillin
Cedin
Cemidon
Chemiazid
Chemidon
Cortinazine
Cotinazin
Cotinizin
Defonin
Dibutin
Diforin
Dinacrin
Ditubin
DOW-ISONIAZID
Ebidene
Eralon
Ertuban
Eutizon
Evalon
Fimalene
FSR 3
Ftivazide
GINK
HIA
Hidranizil
Hidrasonil
Hidrulta
Hidrun
Hycozid
Hydrazid
Hydrazide
Hydrazide, isonicotinic acid
Hyozid
HYZYD
Ido-tebin
Idrazil
Inah
INH
Inizid
Iscotin
Isidrina
Ismazide
Isobicina
Isocid
Isocidene
Isocotin
Isohydrazide
Isolyn
Isonerit
Isonex
Isoniacid
Isoniazid
Isoniazid SA
Isoniazida
Isoniazide
Isonicazide
Isonicid
Isonico
Isonicotan
Isonicotil
Isonicotinate hydrazide
Isonicotinhydrazid
Isonicotinic acid hydrazide
Isonicotinic acid vanillylidenehydrazide
Isonicotinic hydrazide
Isonicotinohydrazide
Isonicotinoyl hydrazide
Isonicotinoylhydrazide
Isonicotinsaeurehydrazid
Isonicotinsäurehydrazid
Isonicotinyl hydrazide
Isonicotinyl hydrazine
Isonicotinylhydrazine
Isonide
Isonidrin
Isonikazid
Isonilex
Isonin
Isonindon
Isonirit
Isoniton
Isonizide
|
Isopyrin
Isotamine
Isotebe
Isotebezid
Isotinyl
Isozide
Isozyd
Laniazid
Laniozid
Mybasan
Neoteben
Neo-Tizide
Neoxin
Neumandin
Nevin
Niadrin
Nicazide
Nicetal
Nicizina
Niconyl
Nicotibina
NICOTIBINE
Nicotisan
Nicozide
Nidaton
Nidrazid
Nikozid
Niplen
Nitadon
NSC-9659
NYDRAZID
Nyscozid
Pelazid
Percin
Phthisen
Phthivazid
Phthivazide
Pycazide
Pyreazid
Pyricidin
Pyridicin
Pyridine-4-carboxylate hydrazide
Pyridine-4-carboxylic acid hydrazide
Pyrizidin
Raumanon
Razide
Retozide
Rifamate
Rimicid
RIMIFON
Rimiphone
Rimitsid
Robiselin
Robisellin
Roxifen
Sanohidrazina
Sauterazid
Sauterzid
STANOZIDE
TB-Phlogin
TB-Razide
TB-Vis
Tebecid
Tebenic
Tebexin
Tebilon
Tebos
Teebaconin
Tekazin
Tibazide
Tibemid
Tibison
Tibivis
Tibusan
Tubazid
Tubazide
Tubeco
Tubecotubercid
Tuberian
Tubicon
Tubilysin
Tubomel
Tyvid
Unicocyde
Unicozyde
Vanillylidenehydrazide, isonicotinic acid
Vazadrine
Vederon
Zidafimia
Zinadon
Zonazide
|
|
22 |
|
Iron Supplement |
|
|
|
|
|
23 |
|
Anti-Bacterial Agents |
|
|
|
|
|
24 |
|
Anti-Infective Agents |
|
|
|
|
|
25 |
|
Antitubercular Agents |
|
|
|
|
|
Interventional clinical trials:
(show all 20)
# |
Name |
Status |
NCT ID |
Phase |
Drugs |
1 |
A Phase III, Safety Extension Study in Patients With Erythropoietic Protoporphyria (EPP) |
Completed |
NCT04578496 |
Phase 3 |
Afamelanotide |
2 |
A Phase III, Multicentre, Double-Blind, Randomized, Placebo-Controlled Study to Confirm the Safety and Efficacy of Subcutaneous Bioresorbable Afamelanotide Implants in Patients With Erythropoietic Protoporphyria (EPP) |
Completed |
NCT01605136 |
Phase 3 |
Afamelanotide;Placebo |
3 |
A Phase III, Multicentre, Randomised, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Subcutanenous Bioresorbable CUV1647 Implants in Patients With Erythropoietic Protoporphyria (EPP) |
Completed |
NCT04053270 |
Phase 3 |
Afamelanotide;Placebo |
4 |
A Phase III, Multicentre, Double-Blind, Randomised, Placebo-Controlled Study to Confirm the Safety and Efficacy of Subcutaneous Bioresorbable Afamelanotide Implants in Patients With Erythropoietic Protoporphyria (EPP) |
Completed |
NCT00979745 |
Phase 3 |
Afamelanotide;Placebo |
5 |
Phase III Study of L-Cysteine in Patients With Erythropoietic Protoporphyria |
Completed |
NCT00004940 |
Phase 3 |
cysteine hydrochloride |
6 |
Sorbent Therapy of the Cutaneous Porphyrias |
Completed |
NCT01422915 |
Phase 2, Phase 3 |
Colestipol |
7 |
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy, Safety, and Tolerability of MT-7117 in Adults and Adolescents With Erythropoietic Protoporphyria or X-Linked Protoporphyria |
Completed |
NCT04402489 |
Phase 3 |
Placebo;MT-7117 Low Dose;MT-7117 High Dose |
8 |
A Phase 3, Multicenter, Open-label, Long-term, Extension Study to Evaluate Safety and Tolerability of Oral Dersimelagon (MT-7117) in Subjects With Erythropoietic Protoporphyria (EPP) or X-Linked Protoporphyria (XLP) |
Active, not recruiting |
NCT05005975 |
Phase 3 |
MT-7117 |
9 |
A Phase II, Multicentre, Double-Blind, Randomised, Placebo-Controlled Study to Confirm the Safety and Efficacy of Subcutaneous Bioresorbable Afamelanotide Implants in Patients With Erythropoietic Protoporphyria (EPP) |
Completed |
NCT01097044 |
Phase 2 |
Afamelanotide;Placebo |
10 |
A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy, Safety, and Tolerability of MT-7117 in Subjects With Erythropoietic Protoporphyria |
Completed |
NCT03520036 |
Phase 2 |
MT-7117 low dose;MT-7117 high dose;Placebo |
11 |
(AURORA) A Randomized, Double-blind, Placebo-Controlled Study of Bitopertin to Evaluate the Safety, Tolerability, Efficacy, and Protoporphyrin IX (PPIX) Concentrations in Participants With Erythropoietic Protoporphyria (EPP) |
Recruiting |
NCT05308472 |
Phase 2 |
DISC-1459;Placebo |
12 |
Effect of Oral Cimetidine in the Protoporphyrias |
Recruiting |
NCT05020184 |
Phase 2 |
Cimetidine;Placebo |
13 |
Does Exercise and Heat Increase the Lightsensibility in Patients With Erythropoietic Protoporphyria |
Unknown status |
NCT00206869 |
|
|
14 |
Erythropoietic Protoporphyrias: Studies of the Natural History, Genotype-Phenotype Correlations, and Psychosocial Impact |
Completed |
NCT01688895 |
|
|
15 |
7202 Mitoferrin-1 Expression in Erythropoietic Protoporphyria (Porphyria Rare Disease Clinical Research Consortium (RDCRC) |
Completed |
NCT01880983 |
|
|
16 |
Effect of Oral Iron Therapy on Erythrocyte Protoporphyrin Levels in the Erythropoietic Protoporphyrias |
Completed |
NCT02979249 |
|
Oral Iron |
17 |
Light Exposure Patterns and Symptoms Among Patients With Erythropoietic Protoporphyria |
Completed |
NCT03682731 |
|
|
18 |
Study of Cysteine Hydrochloride for Erythropoietic Protoporphyria |
Completed |
NCT00004831 |
|
cysteine hydrochloride |
19 |
Oral Iron Therapy in Erythropoietic Protoporphyria |
Not yet recruiting |
NCT05572125 |
|
|
20 |
Quantification of the Effects of Isoniazid Treatment on Erythrocyte and Plasma Protoporphyrin IX Concentration and Plasma Aminolevulinic Acid in Patients With Erythropoietic Protoporphyria |
Terminated |
NCT01550705 |
|
Isoniazid |
|